IncellDx, Inc. Presents First Study Using Their Novel OncoBreast 3Dx Breast Cancer Technology
1/8/2013 9:19:39 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--IncellDx scientists presented data using IncellDx’s proprietary OncoBreast 3Dx™ technology to multiplex protein markers for tumor type (E-cadherin) and ER status, markers for her-2 neu protein and mRNA as well as DNA cell cycle and ploidy, all in intact tumor cells in suspension. The study, presented at the 25th Annual CSU Biotechnology Symposium by Amanda Chargin and co-authored by Keith Shults, demonstrated the feasibility of multiplexing proteins, mRNA and DNA cell cycle using flow cytometry on breast cancer cells obtained by fine needle aspiration.
comments powered by